The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 30, 2021

Filed:

Aug. 22, 2018
Applicant:

Procella Therapeutics Ab, Tullinge, SE;

Inventors:

Kenneth R. Chien, Cambridge, MA (US);

Jonathan Clarke, Stockholm, SE;

Chuen Yan Leung, Stockholm, SE;

Assignee:

Procella Therapeutics AB, Tullinge, SE;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/073 (2010.01); C12N 5/077 (2010.01); C07K 16/28 (2006.01); A01K 67/027 (2006.01); C12N 15/00 (2006.01); G01N 33/50 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0605 (2013.01); A01K 67/0275 (2013.01); C07K 16/2863 (2013.01); C12N 5/0657 (2013.01); C12N 15/00 (2013.01); G01N 33/5014 (2013.01); G01N 33/5044 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0375 (2013.01); A01K 2267/0393 (2013.01); C12N 2500/98 (2013.01); C12N 2501/415 (2013.01); C12N 2501/727 (2013.01); C12N 2506/02 (2013.01); C12N 2506/45 (2013.01); C12N 2533/90 (2013.01);
Abstract

The present invention provides NRP1 as a cell surface marker for isolating human cardiomyogenic ventricular progenitor cells (HVPs), in particular progenitor cells that preferentially differentiate into cardiac ventricular muscle cells. Additional HVP cell surface markers identified by single cell sequencing are also provided. The invention provides in vitro methods of the separation of NRP1+ ventricular progenitor cells, and the large scale expansion and propagation thereof. Large clonal populations of isolated NRP1+ ventricular progenitor cells are also provided. Methods of in vivo use of NRP1+ ventricular progenitor cells for cardiac repair or to improve cardiac function are also provided. Methods of using the NRP1+ ventricular progenitor cells for cardiac toxicity screening of test compounds are also provided.


Find Patent Forward Citations

Loading…